30
Participants
Start Date
November 3, 2017
Primary Completion Date
January 1, 2020
Study Completion Date
January 1, 2020
Influenza vaccine
"The primary aim of this study is to assess the immunogenicity of booster dose influenza vaccine strategy in patients with rheumatologic diseases and IBD who are receiving immunosuppressive therapies.~Secondary aims of this study include assessment of the safety and clinical efficacy, of booster dose influenza vaccine in the prevention of influenza-like illnesses (ILI) in this patient population"
Clinical Research Center, East Setauket
University of North Carolina, Chapel Hill
OTHER
Stony Brook University
OTHER